期刊文献+

β-tubulin Ⅲ在胃癌中的表达及临床意义 被引量:3

Expression and clinical significance of β-tubulin Ⅲ in gastric cancer
下载PDF
导出
摘要 目的研究β-微管蛋白Ⅲ(β-tubulinⅢ)在胃癌组织中的表达情况,探讨其表达与临床病理特征之间的关系。方法采用免疫组织化学的方法检测β-tubulinⅢ在50例胃癌组织及部分相应癌旁组织中的表达,结合患者的性别、年龄、肿瘤大小、部位、分化程度、Borrmann分型、浸润深度、淋巴结转移和TNM分期等临床病理参数进行综合分析。结果胃癌组织和癌旁组织中的β-tubulinⅢ蛋白阳性表达分别为31例(62.00%)、9例(40.91%),差异无统计学意义(χ2=2.752,P>0.05)。β-tubulinⅢ蛋白T1组阳性表达率为22.22%(2/9),T2组阳性表达率为37.50%(3/8),T3组阳性表达率为78.79%(26/33),三组阳性表达率比较差异有统计学意义(P<0.01,χ2=11.790),Spearman等级相关性分析显示,β-tubulinⅢ蛋白阳性表达与胃癌组织中浸润深度呈负相关(Rs=-0.481,P<0.05);β-tubulinⅢ在无淋巴结转移组中阳性表达率为38.89%(7/18),有淋巴结转移组中阳性表达率为75.00%(24/32),两者比较差异有统计学意义(P<0.05,χ2=6.376);β-tubulinⅢ蛋白阳性表达与患者的性别、年龄、肿瘤大小、部位、分化程度、Borrmann分型及TNM分期均无明显相关(P>0.05)。结论β-tubulinⅢ在胃癌中表达率稍高于癌旁组织,但差异不具有统计学意义。其表达水平与肿瘤浸润深度、淋巴结转移有关。 Objective This study was designed to delineate the expression and significance of β-tubulinⅢ in gastric cancer and to investigate the relationship between its expression and elinicopathologic fea- tures. Methods The expression of β-tubulinⅢ protein in 50 gastric cancer and partial paracareinoma tissues was detected by immunohischemistry and was comprehensively analyzed combined with patients' clinicopathologic parameters including gender, age, tumor diameter, tumor site, differentiation, Borrmann type, infiltration depth, lymph node metastasis and TNM stage. Results The expression of β-tubulinⅢ was positive in 31 gastric cancer (62. 00% ) and 9 (40. 91% ) paracarcinoma tissues with no statistical significance (X2 =2. 752, P 〉 0. 05 ). β-tubulinⅢ expression was correlated with the depth of tumor infiltration. The positive rate of β-tubulinⅢ was 22.22% (2/9) in the T1 group, 37.50% (3/8) in the T2 group and 78.79% (26/ 33 ) in the T3 group with a statistical significance ( P 〈 0. 01, X2 = 11. 790 ). The expression of β-tubulinⅢ was found to have positive correlations with the depth of tumor infiltration in gastric cancer by the Spearman rank test (R2 = - 0. 481, P 〈 0.05 ). The positive rate ofβ-tubulinⅢ in the non-lymph node metastasis group was 38. 89% (7/18) and 75.00% (24/32) in the lymph node metastasis group with a statistical significance ( P 〈 0.05, X2 = 6. 376). The expression of β-tubulinⅢ was not associated with patients' gender, age, tumor diameter, tumor site, differentiation, Bormlann type or TNM stage ( P 〉 0.05 ). Conclusions The expression level of β-tubulinⅢ in gastric cancer tissues was higher compared with that in paracarcinoma tissues with no statistical significance. β-tubulinⅢ expression was correlated with depth of tumor infiltration and lymph node metastasis.
出处 《新医学》 2014年第7期444-447,共4页 Journal of New Medicine
基金 江苏大学医学临床科技发展基金(JLY20120104)
关键词 β-tubulinⅢ 胃癌 免疫组织化学 β-tubulinⅢ Gastric cancer Immunohischemistry
  • 相关文献

参考文献4

二级参考文献26

  • 1Kang YK,Kang WK,Shin DB, et al.Capecitabine/cisplatin versus 5‐fluorouracil/cisplatin as first‐line therapy in patients with advanced gastric cancer: a randomised phase III noninferioritytrial. Annals of Oncology . 2009
  • 2Puglisi F,Cardellino GG,Crivellari D, et al.Thymidine phosphorylase expression is associated with time to progression in patient receiving low dose, docetaxel‐modulated capecitabine for metastatic breast cancer. Annals of Oncology . 2008
  • 3Napieralski R,Ott K,Kremer M, et al.Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant treated gastric cancer patients. Clinical Cancer Research . 2005
  • 4Ichikawa W,Takahashi T,Suto K et al.Gene expressions for thymidylate synthase (TS), orotate phosphoribosyltransferase(OPRT), and thymidine phosphorylase (TP), not dihydro‐ pyrimidine dehydrogenase (DPD), influence outcome of patients (pts) treated with S‐1 for gastric cancer (GC). Journal of Clinical Oncology . 2004
  • 5Rosell R,Scagliotti G,Danenberg KD, et al.Transcripts in pretreatment biopsies from a three‐arm randomized trial in metastatic non‐small‐cell lung cancer. Oncegene . 2003
  • 6Dumontet C,Isaac S,Souquet PJ, et al.Expression of class III beta tubulin in non‐small cell lung cancer is correlated with resistance to taxane chemotherapy. Bulletin du Cancer . 2005
  • 7Urano N,Fujiwara Y,Doki Y, et al.Clinical significance of class III beta‐tubulin expression and its predictive value for resistance to docetaxel‐based chemotherapy in gastric cancer. International Journal of Oncology . 2006
  • 8Kwon HC,Roh MS,Oh SY, et al.Prognostic value of expression of ERCC1, thymidylate synth‐ ase, and glutathione S‐transferase P1 for 5‐fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Annals of Oncology . 2007
  • 9Bernard-Marty,C,Treilleux,I,Dumontet,C.Microtubule-Associated Parameters as Predictive Markers of Docetaxel Activity in Advanced Breast Cancer Patients: Results of a Pilot Study. Clinical Breast Cancer . 2002
  • 10Ferrandina,G.et al.Class Ⅲ beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clinical Cancer Research . 2006

共引文献33

同被引文献26

  • 1Ming Lu,Jing Gao, Xi-cheng Wang, Lin Shen.Expressions of Thymidylate Synthase, Thymidine Phosphorylase, Class Ⅲ β-tubulin, and Excision Repair Cross-complementing Group 1 Predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin[J].Chinese Journal of Cancer Research,2011,23(4):288-294. 被引量:22
  • 2Tahara E. Genetic pathways of two types of gastric earleer[J]. IARC Sci Pub1, 2004, (157) :327-349.
  • 3Jin X, Zhu Z, Shi Y. Metastasis mechanism and gene/protein expression in gastric cancer with distant organs metastasis[J]. Bulletin Du Cancer, 2014,101 (1) : E1-12.
  • 4Honnappa S, Jahnke W, Seelig J, et al. Control of in- trinsically disordered stathmin by multisite phosphoryl- ation[J]. J Biol Chem, 2006,281 (23) :16078- 16083.
  • 5Kim JY, Harvard C, You L, et al. Stathmin is overex- pressed in malignant mesothliom[J]. Anticancer Res, 2007,27(1A) : 39-44.
  • 6Nakashima D, Uzawa K, Kasamatsu A, et al. Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands [ J ]. Int J Cancer, 2006, 118 ( 3 ) : 704-713.
  • 7Akhtar J, Wang Z, Zhang ZP, et al. Lentiviral-media- ted RNA interference targeting statnminl gene in hu- man gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo[J]. J Transl Med, 2013,11 : 212.
  • 8Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotc anticancer drugs [ J ]. Drug Resist Updat, 2007,10(4/5) : 162-181.
  • 9Bhattacharyya B, Panda D, Gupta S, et al. Anti-mitot- ic activity of colchicine and the structural basis for its interaction with tubulin [ J ]. Med Res Rev, 2008,28 (1) : 155-183.
  • 10王婧,田劭丹,陈信义.晚期胃癌治疗进展[J].中国肿瘤临床,2010,37(3):171-175. 被引量:55

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部